Foresite Capital Management III’s Kyntra Bio KYNB Stock Holding History

Foresite Capital Management III’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,231	Closed	-$8.14M	–	7
2021 Q2	$8.14M	Hold	12,231	–	–	8.63%	5
2021 Q1	$10.6M	Hold	12,231	–	–	9.32%	4
2020 Q4	$11.3M	Buy	12,231 +5,331	+77%	+$5.6M	13.18%	4
2020 Q3	$7.09M	Buy	6,900 +5,300	+331%	+$5.7M	5.28%	7
2020 Q2	$1.62M	Hold	1,600	–	–	1.44%	8
2020 Q1	$1.39M	Buy	+1,600	New	+$1.59M	2.21%	9
2017 Q3	–	Sell	-10,000	Closed	-$8.07M	–	23
2017 Q2	$8.07M	Buy	10,000 +6,481	+184%	+$4.51M	2.64%	11
2017 Q1	$2.17M	Buy	+3,519	New	+$2.14M	0.83%	18

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foresite Capital Management III's KYNB Position: Q3 2021 in Review

Foresite Capital Management III sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 12,231 shares — an estimated $8.14M sold.

Foresite Capital Management III first reported a position in KYNB in Q1 2017 and held it in 8 quarters. The position peaked at $11.3M in Q4 2020. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Foresite Capital Management III reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
Foresite Capital Management III sold 12,231 Kyntra Bio shares in Q3 2021, an estimated $8.14M.
Foresite Capital Management III first reported a position in Kyntra Bio in Q1 2017 and held it in 8 quarters.
Foresite Capital Management III's Kyntra Bio position peaked at $11.3M in Q4 2020.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Foresite Capital Management III's 13F filing for Q3 2021, filed 12 Nov 2021.